• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Composition for muscle regeneration and recovery. The present invention relates to a composition comprising citrulline malate, caffeine, L-glutamine, taurine, L-arginine and L-leucine. It can be a pharmaceutical or nutritional composition and is used mainly for muscle recovery and regeneration, especially in cases of intense physical exercise. (Machine-translation by Google Translate, not legally binding)
    公开号:ES2794324A1
    申请号:ES201930439
    申请日:2019-05-17
    公开日:2020-11-17
    发明作者:Ayuso Juan Francisco Mielgo；Martínez Alfredo Córdova；García Alberto Caballero
    申请人:Universidad de Valladolid；
    IPC主号:
    专利说明:

    [0002] Composition for muscle regeneration and recovery
    [0004] The present invention relates to an amino acid-based composition and its use especially for muscle recovery and regeneration. It is an energizing and anti-catabolic composition that is especially indicated for oral administration in cases of intense physical exercise.
    [0006] The present invention can be found in the field of pharmaceutical or nutritional compositions.
    [0008] BACKGROUND OF THE INVENTION
    [0010] Proper recovery is one of the pillars of the athlete since he needs to be as soon as possible as well as possible to be able to continue training every day and be able to perform at his best in competitions. In this sense, nutritional recovery is one of the most important since it provides everything necessary so that both energy and muscle structure are responses. Thus, the different international sports nutrition societies indicate that the best post-exercise recovery is the intake of an adequate amount of carbohydrates together with high-quality proteins. Thus, the intake of maltodextrin with branched amino acids may be a good option according to these societies. However, it is considered that recovery could be improved if other compounds are added.
    [0012] There are energizing products on the market, either in the form of drinks or in solid form (capsules, powder, etc.), especially indicated for consumption in cases of effort or intense physical exercise, however, these products have only been thought and formulated from the anabolic point of view indicating their effects on the regeneration of muscle fiber. Other products only refer to a specific aspect, but none are known with the combination that is proposed in the present invention and that presents the effects of the same.
    [0014] DESCRIPTION OF THE INVENTION
    [0016] In a first aspect, the present invention relates to a composition characterized by comprising citrulline malate, caffeine, L-glutamine, taurine, L-arginine, and L-leucine.
    [0018] Citrulline malate is the name given to the equimolar (1: 1) mixture of L-Citrulline (C6H13N3O3 - 2-Amino-5- (carbamoylamino) pentanoic acid) and DL-malate (C4H6O5, ionized form of malic acid : 2-hydroxy 1,4-butanedioic acid).
    [0020] Preferably, the caffeine comprising the invention is anhydrous caffeine.
    [0022] In another preferred embodiment, the composition consists of citrulline malate, caffeine, L-glutamine, taurine, L-arginine, and L-leucine.
    [0024] In another preferred embodiment, the composition further comprises at least one excipient or a food ingredient.
    [0026] In a particular embodiment, the composition comprises the following amounts of the components expressed in% by weight with respect to the final composition:
    [0030] the total sum of the amounts of the components of the composition being 100%.
    [0032] In another preferred embodiment, the composition is in a form adapted for oral administration. Said adapted form refers to a physical state that can allow its oral administration. Preferably, the composition is in powder form (anhydrous) or dissolved in a drinkable liquid, such as water, juice, milk, etc.
    [0034] More preferably, the composition is in powder form for solution in single-dose sachets.
    [0036] In a particular embodiment, each single-dose sachet comprises or consists of: Minimum quantity (g) Maximum quantity (g)
    [0037] Citrulline malate 3.00 6.00
    [0038] Anhydrous caffeine 0.10 0.20
    [0039] Glutamine 3.00 5.00
    [0040] Taurine 0.50 2.00
    [0041] Arginine 1.00 3.00
    [0042] Leucine 2.00 4.00
    [0044] More preferably, each single-dose sachet comprises or consists of:
    [0045] citrulline malate 4.0 g
    [0046] anhydrous caffeine 0.1 g
    [0047] L-glutamine 4.0 g
    [0048] taurine 2.0 g
    [0049] L-arginine 1.0 g
    [0050] L-leucine 3.0 g
    [0052] The composition of the invention can be administered together with proteins and carbohydrates.
    [0054] Thus, for example, in a preferred embodiment the composition is administered with carbohydrates that are preferably selected from the list comprising: maltodextrin, fructose and combinations of both.
    [0056] In another preferred embodiment the composition is administered in conjunction with whey proteins.
    [0058] In a particular embodiment, the composition of the invention is a pharmaceutical composition. The pharmaceutical composition is one that has at least one application in improving the physical or physiological or psychological well-being of a subject, which implies an improvement in the general state of their health or reduction of the risk of disease.
    [0060] In a particular embodiment, the pharmaceutical composition further comprises, at the minus, a pharmaceutically acceptable carrier and / or excipient.
    [0062] The "vehicle" or carrier is preferably an inert substance. The function of the vehicle is to facilitate the incorporation of other compounds, allow a better dosage and administration or give consistency and shape to the pharmaceutical composition. Therefore, the vehicle is a substance that It is used in the medicine to dilute any of the components of the pharmaceutical composition of the present invention to a certain volume or weight; or that even without diluting said components it is capable of allowing a better dosage and administration or giving consistency and shape to the medicine When the presentation form is liquid, the pharmaceutically acceptable carrier is the diluent.
    [0064] The term "excipient" refers to a substance that helps the absorption of any of the components of the composition of the present invention, stabilizes said components or helps the preparation of the pharmaceutical composition in the sense of giving it consistency or providing flavors that make it more pleasant. Thus, excipients could have the function of keeping the components together such as starches, sugars or celluloses, sweetening function, coloring function, protection function of the drug such as for example to isolate it from the air and / or humidity, filling function of a tablet, capsule or any other form of presentation. Therefore, the term "excipient" is defined as that material that, included in galenic forms, is added to the active principles or their associations to enable its preparation and stability, modify its organoleptic properties or determine the physicochemical properties of the pharmaceutical composition. ethics and its bioavailability. The "pharmaceutically acceptable" excipient must allow the activity of the compounds of the pharmaceutical composition, that is, it must be compatible with said components.
    [0066] Furthermore, as understood by the person skilled in the art, the excipient and the vehicle must be pharmacologically acceptable, that is, the excipient and the vehicle are allowed and evaluated so that they do not cause harm to the organisms to which it is administered.
    [0068] Alternatively to the pharmaceutical composition, the composition of the invention can also be a food or nutritional composition.
    [0069] The term "food composition" of the present invention refers to that food that, regardless of providing nutrients to the subject who takes it, beneficially affects one or more functions of the body, in a way that provides a better state of health and well-being. The term "food composition" of the present invention can be used synonymously with nutritional composition, functional food or food for specific nutritional purposes or medicinal food.
    [0071] The food composition of the present invention can comprise food ingredients. A food ingredient is any substance or combination of edible substances suitable for providing flavor, nutrition, color, volume, texture or other flavor, stability, acidity, thickness, anti-caking, etc.
    [0073] In a particular embodiment, the food composition is a food supplement. "Food supplement" within the framework of the present invention is used equivalently to a food supplement. The term "food supplement" is a food composition intended to supplement food. It is not presented as a substitute for a conventional food or as a single component of a meal or diet, but as a supplement to the diet.
    [0075] Another aspect of the invention refers to the non-therapeutic use of the composition defined in the first aspect of the invention for muscle regeneration and recovery, to improve athletic muscle performance, muscle strength, muscle mass, vigor, endurance, to improve physiological recovery and to avoid fatigue. More preferably, the invention refers to the non-therapeutic use of the composition defined in the first aspect of the invention for muscle regeneration and recovery, especially in cases of exertion or physical exercise, the composition being able to be administered before or after performing the exercise. physical.
    [0077] The composition is especially suitable for athletes, the elderly and sick patients.
    [0079] Another aspect of the invention relates to the composition defined in the first aspect for use as a medicine. Most preferably for use in the treatment and / or prevention of diseases related to the loss and weakening of mass muscle, such as sarcopenia, fibromyalgia, or fatigue. It also intervenes in the protection against oxidative stress. Due to its effect on blood flow, it has a vasodilator effect and therefore can contribute to regulating blood pressure.
    [0081] In the present invention, the term "treatment" refers to combating the effects caused as a consequence of a disease or pathological condition of interest in a subject (preferably a mammal, and more preferably a human) including: (i) inhibiting the disease or pathological condition, that is, stop its development;
    [0082] (ii) alleviating the disease or pathological condition, that is, causing regression of the disease or pathological condition or its symptomatology;
    [0083] (iii) stabilize the disease or pathological condition.
    [0085] In the present invention, the term "prevention" refers to preventing the onset of the disease, that is, preventing the disease or pathological condition from occurring in a subject (preferably a mammal, and more preferably a human), in particular, when said subject has a predisposition for the pathological condition.
    [0087] The composition of the invention, whether it is a pharmaceutical or a food composition, is administered to a subject preferably in a daily dose such that the sum of the amounts of citrulline malate, caffeine, L-glutamine, taurine, L-arginine and L- administered leucine is between 9 and 21 grams per day, more preferably 14 grams / day. However, the administered dose can be adjusted depending on the age, weight, physical condition of the subject.
    [0089] More preferably, the dose administered daily is a dose of 14.1 g, the composition of which is as follows:
    [0092] This composition is preferably arranged in single-dose sachets, so that one sachet is administered each day.
    [0094] The composition of the present invention has properties with enhancing effects of which the following stand out:
    [0095] - improves blood flow thereby delaying fatigue,
    [0096] - the combination of amino acids enhances the anabolic effect by increasing the endogenous production of growth hormone,
    [0097] - It also has antioxidant effects and, therefore, contributes to the reduction of oxidative stress.
    [0098] - It is a nervous and metabolic stimulant, improving absorption and bioavailability and therefore its effects,
    [0099] - through malate provides energy as it favors the formation of ATP (adenosine triphosphate),
    [0100] - malate also helps reduce muscle pain,
    [0101] - decreases metabolic acidosis in addition to eliminating ammonia and toxic nitrogen metabolites,
    [0102] - it is anti-catabolic,
    [0103] - improves immune function and therefore recovery.
    [0105] For all these reasons, the present invention at the proposed doses is a perfect combination due to its agonist effects to facilitate muscle recovery and regeneration.
    [0107] Throughout the description and claims the word "comprise" and its variants are not intended to exclude other technical characteristics, additives, components or steps. For those skilled in the art, other objects, advantages and characteristics of the invention will emerge partly from the description and partly from the practice of the invention. The following examples are provided by way of illustration, and are not intended to be limiting of the present invention.
    [0109] EXAMPLES
    [0111] Next, the invention will be illustrated by means of tests carried out by the inventors, which show the effectiveness of the product of the invention Example 1: Preparation of the composition.
    [0112] From the following amounts the composition of the invention was prepared:
    [0117] Compounding was made by mixing the corresponding amounts of powder from each product (powder components were purchased independently from BuckPower ™ trade house). The final mixture in powder form was mixed with water to be administered to the athletes.
    [0119] Example 2: Effect of the composition of the invention on muscle damage and endogenous recovery of athletes
    [0120] 1. Material and methods.
    [0121] 1.1. Participants
    [0122] Twenty-eight elite male rowers (30.43 ± 4.65 years; 23.92 ± 1.85 kg / m2 and 8.3 ± 1.15% of fat mass) that belonged to a rowing club of the first rowing league in Spain (ACT) participated in this non-placebo controlled randomized trial. All athletes performed the same training sessions during the competitive period consisting of 1.5 hours per day, 6 days per week for 10 weeks. In addition, the dietician-nutritionist of the club developed an individual diet for each rower for each day of the week. The diets were proposed using previously established energy and macronutrient guidelines for adequate athletic performance, and were based on the volume and training load, and the personal characteristics of each participant.
    [0124] A medical examination was performed before the study began to verify that the participants did not have any illness or injury. In addition, all the participants declared that they did not consume illegal drugs or took medications or other ergogenic products (including previously HMB or creatine) that could affect the analytical and / or anthropometric variables studied.
    [0125] All participants were fully informed of all aspects of the study and signed an informed consent statement.
    [0127] 1.2. Experimental protocol and evaluation plan.
    [0128] This study was designed as a double-blind, randomized, non-placebo-controlled trial to analyze the effects of oral supplementation of the composition prepared in Example 1 (hereinafter, the composition of the invention) for 10 weeks on muscle damage levels ( Creatine kinase - CK) as well as in muscle recovery measured by the catabolic hormone cortisol, the anabolic hormone testosterone and the relationship between both hormones through the testosterone / cortisol ratio. Each day a composition (corresponding to a dose) as prepared in Example 1 was administered.
    [0130] Participants were randomly assigned into four different groups using a stratified block design. An independent statistician generated the randomization sequence:
    [0131] 1. Control group (GCHO, n = 11, height: 179 ± 10 cm and body mass: 75.2 ± 7.9 kg) treated only with carbohydrates (CHO) in an amount of 1 g / kg;
    [0132] 2. Group treated with 1 g / kg of CHO to whey proteins (0.3 g / kg) that included 3 g of L-leucine (GCHOP, n = 11, height: 180 ± 7cm and mass body weight: 75.5 ± 7.3kg) and
    [0133] 3. Group treated with the composition of the invention (GCPW, n = 10, height: 178 ± 8cm and body mass: 74.5 ± 6.3kg) that was treated with 1 dose of the invented compound together with 1 g / kg CHO 0.3 g / kg of whey proteins and the composition of the invention.
    [0135] All participants attended the laboratory (08:30 h) to draw blood at two specific points during the study: 1) at the beginning of the study (T1) and 2) after treatment (T2, the day after 10 weeks of treatment).
    [0137] The 3 groups took the previously specified treatments during the 6 days of weekly training in the form of a recovery shake in the half hour after finishing the exercise as specified in the recovery protocols of the most important sports nutrition societies. An independent club nutritionist made the shakes with the amount of supplements individual rowers, therefore, each rower and researcher did not know what supplements they were taking. The CHO, specifically 75% was maltodextrin and 25% of fructose and the whey protein were obtained from the FullGas® commercial company (Fullgas Sport, SL, 20115 Astigarraga, Guipúzcoa (Spain).
    [0139] 1.3. Blood test
    [0140] Blood samples (10 ml) were collected at each time (T1 and T2) from the antecubital vein of all athletes, under baseline conditions, after an overnight fast and after 36 hours without exercise. In addition, for blood collection, the athletes arrived at the laboratory at 8:30 am and upon arrival they sat comfortably for 30 minutes. The blood sample was left at room temperature for 10 minutes before centrifugation for 15 minutes at 4 ° C and 3,000 rpm. The serum was then separated and stored in aliquots at -20 ° C until analysis. All analyzes were carried out according to the manufacturer's instructions.
    [0142] Total testosterone : Total testosterone was measured using enzyme-linked immunosorbent assay (ELISA) kits (DRG testosterone ELISA kit®, DRG Instruments GmbH, Marburg / Lahn, Germany). The intra-assay coefficient of variation (CV) was 4.3% and the inter-assay CV was 9.2%.
    [0144] Cortisol: Serum cortisol levels were measured by an enzyme-linked fluorescence assay with the aid of a multiparametric analyzer (Minividas®, Biomerieux, Marcy l'Etoile, France). The substrate, 4-methyl umbelipherone, was used and was capable of fluorescent emission at 450nm, after stimulation at 370nm. The intra-assay CV was 5.7% and the inter-assay CV was 6.2%.
    [0146] Testosterone / cortisol ratio calculations: Testosterone / cortisol ratio was calculated from total testosterone and cortisol concentrations.
    [0148] 1.4. Statistic analysis
    [0149] Analyzes were performed using SPSS software version 24.0 (SPSS, Inc., Chicago, Illinois, USA) and Microsoft Excel (Microsoft Excel Software version 19). Data are presented as means and standard deviations. Significance indicated statistics when p <0.05. The percentage changes of the variables studied in each study group between the reference tests (T1) and post-treatment (T2) were calculated as A (%): [(T2 - T1) / T1] * 100). The Shapiro-Wilk test was used to determine the normality of the data (n <50), therefore, we used parametric formulas. Levene's test was applied to measure the homoscedasticity of the variances.
    [0151] In addition, the two-way repeated measures analysis of variance (ANOVA) test was used to examine the effects of interactions (time x supplementation group) between supplementation groups (GCHO, GCHOP, and GCPW) for the damage parameters. muscle (CK) and recovery (testosterone / cortisol and testosterone / cortisol ratio).
    [0153] The A (%) of the study parameters were compared using a one-way analysis of covariance with the category of supplements as a fixed factor. A post hoc Bonferroni test was applied for pairwise comparisons between groups. Similarly, the differences from T1 to T2 in each group were assessed by a parametric or non-parametric dependent t-test.
    [0155] Effect sizes between participants were calculated using a partial eta square (q2p). Given that this measure is likely to overestimate the effect sizes, the values were interpreted according to (40), which is indicated as having no effect if 0 <q2p <0.05; a minimal effect if 0.05 <q2p <0.26; a moderate effect if 0.26 <q2p <0.64; and a strong effect if q2p> 0.64 (40) .2
    [0157] 2. Results
    [0158] Table 1 shows the behavior of muscle damage (creatine kinase) and muscle recovery (cortisol, testosterone and testosterone / cortisol ratio) in the 3 study groups at the beginning and at the end of 10 weeks of treatment. It was observed that there was a different behavior of these parameters throughout the study depending on the treatment group (p <0.01). In this sense, while it was observed that in T1 except for basal cortisol where significant differences were observed between the HOC group and the GCPW (p <0.05) there were no significant differences between groups, in T2 significant differences were observed in all the parameters studied between groups. Especially differences were observed in the CK between the GCHO group and the GCPW, which shows less muscle damage in the GCPW than in the GCHO group. On the other hand, cortisol, testosterone, and the testosterone / cortisol ratio showed significant differences (p <0.01) between the GCHO and GCHOP groups with respect to GCPW in T2, with no differences being observed between GCHO with respect to the GCHOP group (p> 0.05). These data show better recovery and less endogenous stress in the GCPW than in the other 2 groups in T2.
    [0160] Table 1. Behavior of muscle damage (creatine kinase) and muscle recovery (cortisol, testosterone and testosterone / cortisol ratio) in the 3 study groups at the beginning and at the end of 8 weeks of treatment.
    [0161] T1 T2 P (TXG) n 2 2 p
    [0162] GCHO * 215.22 ± 118.92 326.83 ± 302.70
    [0163] GCHOP 264.56 ± 287.02 228.89 ± 174.86 0.004 0.191 GCPW * 266.89 ± 198.28 155.89 ± 112.98 a
    [0165] GCHO * 16.56 ± 2.94 20.37 ± 4.26
    [0166] GCHOP 18.98 ± 3.83 19.68 ± 3.87 <0.001 0.329 GCPW * 19.93 ± 4.22 a 16.08 ± 2.41 ab
    [0168] GCHO * 5.08 ± 1.33 4.52 ± 0.80
    [0169] GCHOP 5.12 ± 1.37 5.31 ± 1.67 <0.001 0.282 GCPW * 4.90 ± 0.84 5.88 ± 1.33 a
    [0171] GCHO * 32.30 ± 13.10 23.38 ± 6.92
    [0172] GCHOP 27.53 ± 7.87 28.66 ± 12.26 <0.001 0.300 GCPW * 25.35 ± 5.23 37.50 ± 10.26 ab
    [0173] The data are expressed as mean ± standard deviation.
    [0174] P: Interaction time per group obtained by means of a 2-factor ANOVA:
    [0175] *: Significant differences between study phases (T1 Vs T2). p <0.05.
    [0176] a: Significant differences with respect to the GCHO group. p <0.05.
    [0177] b: Significant differences with respect to the GCHOP group. p <0.05.
    [0179] Table 2 shows the percentage of change in the parameters of muscle damage (creatine kinase) and muscle recovery (cortisol, testosterone and ratio testosterone / cortisol) in the 3 study groups between the start and the end of treatment (T1-T2). In it, it is observed that there were significant differences in the changes throughout the study between study groups (P <0.01). Specifically, and confirming what Table 1 indicates, differences in creatine kinase were observed between the GCHO group (52.40 ± 123.13%) and the GCPW group (-32.04 ± 31.05%), which shows a better recovery of muscle damage in the GCPW than in the GCHO group throughout the study. On the other hand, cortisol, testosterone and the testosterone / cortisol ratio showed significant differences (p <0.01) between the GCHO and GCHOP groups with respect to GCPW in T2 throughout the study, with no differences being observed between GCHO with respect to the GCHOP group (p> 0.05). These data show that there was better recovery and less endogenous stress in the GCPW than in the other 2 groups throughout the study.
    [0181] Table 2 . Percentage of change in the parameters of muscle damage (creatine kinase) and muscle recovery (cortisol, testosterone and testosterone / cortisol ratio) in the 3 study groups between the start and the end of treatment (T1-T2).
    [0182] Group A (T1-T2) P 2 n 2 p
    [0183] CREATIN-KINASE GCHOP 1.67 ± 44.72 0.008 0.174 GCPW -32.04 ± 31.05a
    [0185] CORTISOL basal GCHOP 7.75 ± 30.13 <0.001 0.293 GCPW -16.83 ± 18.23 ab
    [0187] TESTOSTERONE GCHOP 3.54 ± 21.41 <0.001 0.282 TOTAL GCPW 20.17 ± 18.38 ab
    [0188] GCHO INDEX -21.85 ± 26.58
    [0189] TESTOSTERONE / GCHOP 10.49 ± 58.45 <0.001 0.278 CORTISOL GCPW 56.08 ± 59.36 ab
    [0190] The data are expressed as mean ± standard deviation.
    [0191] A (T1-T2) = ((T2-T1) / T1) x100
    [0192] P: Interaction of the group obtained through a 1-way ANOVA
    [0193] a: Significant differences with respect to the GCHO group. p <0.05.
    [0194] b: Significant differences with respect to the GCHOP group. p <0.05.
    权利要求:
    Claims (15)
    [1]
    1. Composition characterized by comprising:
    - citrulline malate,
    - caffeine,
    - L-glutamine,
    - taurine,
    - L-arginine and
    - L-leucine.
    [2]
    2. Composition according to claim 1, characterized in that it also comprises at least one excipient or a food ingredient.
    [3]
    3. Composition according to claim 1, characterized in that it consists of citrulline malate, caffeine, L-glutamine, taurine, L-arginine and L-leucine.
    [4]
    Composition according to any of the preceding claims, characterized in that it comprises the following amounts of the components expressed in% by weight with respect to the final composition:

    [5]
    5. Composition according to any of the preceding claims, characterized in that it is adapted for oral administration.
    [6]
    Composition according to any of the preceding claims, characterized in that it is in powder form or dissolved in a drinkable liquid.
    [7]
    Composition according to any of the preceding claims 5 to 6, characterized in that it is in powder form for solution with presentation in single-dose sachets.
    [8]
    Composition according to any of the preceding claims 5 to 7, characterized in that each single-dose sachet comprises:

    [9]
    9.
    [10]
    Composition according to any of the preceding claims, characterized in that it is a pharmaceutical composition or a food composition.
    [11]
    11. Non-therapeutic use of the composition defined in any of the preceding claims for muscle regeneration and recovery, to improve athletic muscle performance, muscle strength, muscle mass, vigor, endurance, to enhance physiological recovery and to avoid fatigue.
    [12]
    12. Use according to claim 11 for muscle regeneration and recovery in cases of physical exercise, where the composition is administered before or after performing physical exercise.
    [13]
    Composition according to any of claims 1-10 for use as a medicine.
    [14]
    Composition according to claim 13 for use in the treatment of diseases related to the loss or weakening of muscle mass.
    [15]
    15. Composition for use according to claim 14 for use in the treatment of sarcopenia or fibromyalgia.
    类似技术:
    公开号 | 公开日 | 专利标题
    ES2861583T3|2021-10-06|Rapid-acting oral preparation that can increase the level of arginine in the blood and comprises citrulline and arginine
    US9066953B2|2015-06-30|Methods for increasing endurance and fat metabolism in humans
    US20070202200A1|2007-08-30|Method of inhibiting weight regain after weight loss
    Valenzuela et al.2019|Supplements with purported effects on muscle mass and strength
    US10660870B2|2020-05-26|Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting
    TW200410680A|2004-07-01|Nutritiona compositions
    JP2009539405A|2009-11-19|Compositions, methods and kits for increasing weight loss while reducing lean body mass loss
    TW201417806A|2014-05-16|Methods for improving linear growth response in children
    TW202015668A|2020-05-01|Methods of manufacturing amino acid compositions
    TW201424728A|2014-07-01|Compositions and methods for increasing human growth hormone levels
    BR112020009765A2|2020-11-03|compositions and methods that use a combination of autophagy inducer and high protein content for inducing autophagy
    Wu et al.2021|Role of L-arginine in nitric oxide synthesis and health in humans
    US9642825B2|2017-05-09|Bio-available N-acetyl creatine species and compositions thereof
    ES2743955T3|2020-02-21|Compositions comprising cinnamaldehyde and zinc and methods for using such compositions
    JP2004520341A|2004-07-08|Use of betaine in functional products with blood pressure lowering effects
    US20160303176A1|2016-10-20|Nutritional supplement
    ES2794324B2|2021-04-14|Composition for muscle regeneration and recovery
    CN108186631B|2020-09-25|Pharmaceutical composition and preparation method and application thereof
    BR112020007447A2|2020-12-08|USE OF AMINO ACIDS SUPPLEMENTATION IN THE SYNTHESIS OF ENHANCED MUSCLE PROTEIN
    US20160303177A1|2016-10-20|Nutritional supplement
    US20080108698A1|2008-05-08|Nutrient Supplement and Use of the Same
    ES2815351T3|2021-03-29|Marine peptides and fish nucleotides, compositions and their uses for lowering blood glucose
    ES2848349A1|2021-08-06|Composition for the prevention and treatment of iron deficiency and anemia |
    US20210113501A1|2021-04-22|Method of administering beta-hydroxy-beta-methylbutyrate |
    ES2775610T3|2020-07-27|Compositions and methods for treating malnutrition
    同族专利:
    公开号 | 公开日
    ES2794324B2|2021-04-14|
    WO2020234499A1|2020-11-26|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    CA2692371A1|2010-02-11|2011-08-11|Michel Grise|Anti-fatigue composition|
    US20130323324A1|2012-06-01|2013-12-05|Franco Cavaleri|Vanadium and vanadyl amino acid complexes|
    US20140072524A1|2012-09-13|2014-03-13|Henkel Ag & Co. Kgaa|Hair care products with selected aminio functional silicones and cationic plant-based surfactants|
    法律状态:
    2020-11-17| BA2A| Patent application published|Ref document number: 2794324 Country of ref document: ES Kind code of ref document: A1 Effective date: 20201117 |
    2021-04-14| FG2A| Definitive protection|Ref document number: 2794324 Country of ref document: ES Kind code of ref document: B2 Effective date: 20210414 |
    优先权:
    申请号 | 申请日 | 专利标题
    ES201930439A|ES2794324B2|2019-05-17|2019-05-17|Composition for muscle regeneration and recovery|ES201930439A| ES2794324B2|2019-05-17|2019-05-17|Composition for muscle regeneration and recovery|
    PCT/ES2020/070318| WO2020234499A1|2019-05-17|2020-05-18|Composition for muscular regeneration and recovery|
    [返回顶部]